open access

Vol 8 (2023): Continuous Publishing
Original paper
Published online: 2023-07-25
Get Citation

Clinical study of rhino-orbital-cerebral mucormycosis in COVID-19 patients in a regional institute in South India

Shantala Arunkumar1, Renuka Barki1, Deepakakumar Dodamani1, Navya Kiran1, Ajay S. Hatti1, Shamshoddin Ghudusab1, Mamatha Vinay1
·
Ophthalmol J 2023;8:72-80.
Affiliations
  1. S.S. Institute of Medical Sciences and Research Centre, Davangere, Karnataka, India

open access

Vol 8 (2023): Continuous Publishing
ORIGINAL PAPERS
Published online: 2023-07-25

Abstract

BACKGROUND: Rhino-orbital-cerebral mucormycosis (ROCM) is usually seen in immunosuppressed conditions like uncontrolled diabetes mellitus (DM). The pandemic of severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) and its associated immunosuppression and indiscriminate use of corticosteroids emerged as a new risk factor for ROCM during its’ second wave of coronavirus disease 2019 (COVID-19), especially in India. The lack of standardized management protocol for ROCM needs the attention of the ophthalmic community. COVID-19-associated risk factors have been linked to the pathogenesis of ROCM, which reached epidemic proportions during India’s second wave of the pandemic.

The aim of the present study was to document cases of ROCM and to evaluate risk factors, including co-morbidities, clinical characteristics, diagnosis, management, and outcome at tertiary care centers during the Sars-CoV-2 (2021) pandemic.

MATERIAL AND METHODS: It is a retrospective study of 42 patients of biopsy-proven mucormycosis. These patients’ records were reviewed from hospital data. All patients were subjected to complete ophthalmological, ortorhino laringological examination, and imaging studies. The orbital staging was done. Each case was treated by a multidisciplinary approach with functional endoscopic sinus surgery (FESS) and intravenous (i.v.) amphotericin B (AMB). Retrobulbar liposomal AMB and exenteration were performed whenever indicated. Statistical analysis was done using the Chi square test. A p-value ≤ 0.05 was considered significant.

RESULTS: Total 42 patients of ROCM were documented. The mean age was 50.48 years, with a male preponderance (82.9%). 99.8% of patients had diabetes (39 patients) and all patients were COVID-19-positive. Concurrent steroid use was seen in 83.3% where 73.1% of patients had received oxygen support during COVID-19 infection. The most common ophthalmologic presentation was orbital/facial oedema (33) and pain, diminution of vision (24), and ophthalmoplegia (26). Direct nasal endoscopy and biopsy were done to establish a diagnosis. All patients were treated with FESS and i.v. AMB. Retrobulbar AMB was given to 11 patients. Exenteration was done in (n = 4) 10.5% of cases. 41 patients recovered, and one patient died

CONCLUSION: The most significant predisposing factors for developing COVID-19-associated ROCM are corticosteroids and DM. Patients with COVID-19 must be followed up even after recovery. For a favorable outcome with lower mortality in COVID-19 recovered patients, we must have a high index of clinical suspicion with awareness of red flag signs and make a timely diagnosis.

Abstract

BACKGROUND: Rhino-orbital-cerebral mucormycosis (ROCM) is usually seen in immunosuppressed conditions like uncontrolled diabetes mellitus (DM). The pandemic of severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) and its associated immunosuppression and indiscriminate use of corticosteroids emerged as a new risk factor for ROCM during its’ second wave of coronavirus disease 2019 (COVID-19), especially in India. The lack of standardized management protocol for ROCM needs the attention of the ophthalmic community. COVID-19-associated risk factors have been linked to the pathogenesis of ROCM, which reached epidemic proportions during India’s second wave of the pandemic.

The aim of the present study was to document cases of ROCM and to evaluate risk factors, including co-morbidities, clinical characteristics, diagnosis, management, and outcome at tertiary care centers during the Sars-CoV-2 (2021) pandemic.

MATERIAL AND METHODS: It is a retrospective study of 42 patients of biopsy-proven mucormycosis. These patients’ records were reviewed from hospital data. All patients were subjected to complete ophthalmological, ortorhino laringological examination, and imaging studies. The orbital staging was done. Each case was treated by a multidisciplinary approach with functional endoscopic sinus surgery (FESS) and intravenous (i.v.) amphotericin B (AMB). Retrobulbar liposomal AMB and exenteration were performed whenever indicated. Statistical analysis was done using the Chi square test. A p-value ≤ 0.05 was considered significant.

RESULTS: Total 42 patients of ROCM were documented. The mean age was 50.48 years, with a male preponderance (82.9%). 99.8% of patients had diabetes (39 patients) and all patients were COVID-19-positive. Concurrent steroid use was seen in 83.3% where 73.1% of patients had received oxygen support during COVID-19 infection. The most common ophthalmologic presentation was orbital/facial oedema (33) and pain, diminution of vision (24), and ophthalmoplegia (26). Direct nasal endoscopy and biopsy were done to establish a diagnosis. All patients were treated with FESS and i.v. AMB. Retrobulbar AMB was given to 11 patients. Exenteration was done in (n = 4) 10.5% of cases. 41 patients recovered, and one patient died

CONCLUSION: The most significant predisposing factors for developing COVID-19-associated ROCM are corticosteroids and DM. Patients with COVID-19 must be followed up even after recovery. For a favorable outcome with lower mortality in COVID-19 recovered patients, we must have a high index of clinical suspicion with awareness of red flag signs and make a timely diagnosis.

Get Citation

Keywords

COVID-19; rhino-orbital-cerebral mucormycosis; retrobulbar amphotericin B

About this article
Title

Clinical study of rhino-orbital-cerebral mucormycosis in COVID-19 patients in a regional institute in South India

Journal

Ophthalmology Journal

Issue

Vol 8 (2023): Continuous Publishing

Article type

Original paper

Pages

72-80

Published online

2023-07-25

Page views

876

Article views/downloads

212

DOI

10.5603/OJ.2023.0016

Bibliographic record

Ophthalmol J 2023;8:72-80.

Keywords

COVID-19
rhino-orbital-cerebral mucormycosis
retrobulbar amphotericin B

Authors

Shantala Arunkumar
Renuka Barki
Deepakakumar Dodamani
Navya Kiran
Ajay S. Hatti
Shamshoddin Ghudusab
Mamatha Vinay

References (31)
  1. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13(2): 236–301.
  2. Mohammadi R, Meidani M, Mostafavizadeh K, et al. Case series of rhinocerebral mucormycosis occurring in diabetic patients. Caspian J Intern Med. 2015; 6(4): 243–246.
  3. Meyers B, Gurtman A. Phycomycetes. Infectious Diseases 2nd ed. WB Saunders, Philadelphia 1998.
  4. Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020.
  5. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003; 362(9398): 1828–1838.
  6. Bouchara JP, Oumeziane NA, Lissitzky JC, et al. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol. 1996; 70(1): 76–83.
  7. Boelaert JR, Fenves AZ, Coburn JW, et al. Mucormycosis among patients on dialysis. N Engl J Med. 1989; 321(3): 190–191.
  8. Ochi JW, Harris JP, Feldman JI, et al. Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob Agents Chemother. 1988; 32(6): 865–872.
  9. Abedi E, Sismanis A, Choi K, et al. Twenty-five years' experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope. 1984; 94(8): 1060–1062.
  10. Rangel-Guerra R. Mucormycosis. Archives of Neurology. 1985; 42(6): 578.
  11. Honavar SG. Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19. Indian J Ophthalmol. 2021; 69(6): 1361–1365.
  12. Smith HW, Kirchner JA. Cerebral Mucormycosis: A Report of Three Cases. AMA Arch Otolaryngol. 1958; 68(6): 715–726.
  13. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser. 1989; 47: 243–271.
  14. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984; 74(1): 150–160.
  15. Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India — Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol . 2021 Jul;69(7):1670-1692. 2021; 69(7): 1670–1692.
  16. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8): 782–793.
  17. John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel). 2021; 7(4).
  18. Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021; 15(4): 102146.
  19. Hoenigl M, Seidel D, Carvalho A, et al. The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries. SSRN Electronic Journal. .
  20. Bhattacharyya A, Sarma P, Kaur H, et al. Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review. Indian J Pharmacol. 2021; 53(4): 317–327.
  21. Nithyanandam S, Jacob MS, Battu RR, et al. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003; 51(3): 231–236.
  22. Rootman J, Robertson W, Laointe S. Inflammatory diseases. In: Rootman J. ed. Diseases of the Orbit. A Multidiscilinary Aroach 1st ed. JB Lippincott Company 1988: 155–156.
  23. Brunet K, Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Med. 2020; 30(3): 101007.
  24. Manesh A, John AO, Mathew B, et al. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Mycoses. 2016; 59(12): 765–772.
  25. Salmanton-García J, Hoenigl M, Gangneux JP, et al. CPAnet, Mucormycosis ECMM MSG Global Guideline Writing Group, European Confederation of Medical Mycology (ECMM), from the Study Group for Infections in Critically Ill Patients (ESGCIP) and the Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), European Society of Intensive Care Medicine (ESICM), European Confederation of Medical Mycology (ECMM), Mycoses Study Group Education and Research Consortium (MSGERC). A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study. Clin Microbiol Infect. 2017; 23(10): 776.e1–776.e5.
  26. Sipsas NV, Gamaletsou MN, Anastasopoulou A, et al. Therapy of Mucormycosis. J Fungi (Basel). 2018; 4(3).
  27. Lee AS, Lee PWY, Allworth A, et al. Orbital mycoses in an adult subtropical population. Eye (Lond). 2020; 34(9): 1640–1647.
  28. Hirabayashi K, Kalin-Hajdu E, Brodie F, et al. Retrobulbar Injection of Amphotericin B for Orbital Mucormycosis. Ophthalmic Plast Reconstr Surg. 2017; 33(4): e94–e97.
  29. Safi M, Ang MJ, Patel P, et al. Rhino-orbital-cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. Am J Ophthalmol Case Rep. 2020; 19: 100771.
  30. Songu M, Unlu HH, Gunhan K, et al. Orbital exenteration: A dilemma in mucormycosis presented with orbital apex syndrome. Am J Rhinol. 2008; 22(1): 98–103.
  31. Pelton RW, Peterson EA, Patel BC, et al. Successful treatment of rhino-orbital mucormycosis without exenteration: the use of multiple treatment modalities. Ophthalmic Plast Reconstr Surg. 2001; 17(1): 62–66.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Publisher: VM Media Group sp. z o.o., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 310 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl